Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer

NCT00453167 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

35

Enrollment

OTHER_GOV

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Paclitaxel
DRUG: Gemcitabine

Sponsor

National Cancer Center, Korea